Price Action Don’t Lie: Could Advaxis, Inc. Gain Strenght? The Stock Reaches 52 Week Low

Price Action Don't Lie: Could Advaxis, Inc. Gain Strenght? The Stock Reaches 52 Week Low

The stock of Advaxis, Inc. (NASDAQ:ADXS) is a huge mover today! About 638,036 shares traded hands. Advaxis, Inc. (NASDAQ:ADXS) has risen 55.15% since March 3, 2016 and is uptrending. It has outperformed by 46.81% the S&P500.
The move comes after 6 months negative chart setup for the $433.26 million company. It was reported on Oct, 6 by We have $9.92 PT which if reached, will make NASDAQ:ADXS worth $43.33 million less.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Out of 2 analysts covering Advaxis (NASDAQ:ADXS), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Advaxis has been the topic of 2 analyst reports since September 11, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Friday, September 11 by Guggenheim. On Tuesday, September 22 the stock rating was initiated by Barclays Capital with “Overweight”.

According to Zacks Investment Research, “Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body’s immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company’s products in development include Lovaxin C and Lovaxin B, Lovaxin P.”

Insitutional Activity: The institutional sentiment increased to 2.38 in 2016 Q2. Its up 1.20, from 1.18 in 2016Q1. The ratio increased, as 7 funds sold all Advaxis, Inc. shares owned while 14 reduced positions. 11 funds bought stakes while 39 increased positions. They now own 21.74 million shares or 0.17% less from 21.77 million shares in 2016Q1.
Swiss National Bank holds 53,500 shares or 0% of its portfolio. Rhumbline Advisers last reported 39,105 shares in the company. Moreover, Dimensional Fund Limited Partnership has 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 12,189 shares. Tocqueville Asset Management Lp has 53,950 shares for 0.01% of their US portfolio. Cormorant Asset Management Limited Company holds 0.93% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 809,804 shares. Jefferies Grp Limited Liability accumulated 151,672 shares or 0.01% of the stock. Goldman Sachs Grp Inc reported 20,944 shares or 0% of all its holdings. Schwab Charles Management has 0% invested in the company for 44,111 shares. New York State Common Retirement Fund has invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Commonwealth Equity holds 0% or 13,125 shares in its portfolio. Spot Trading Ltd last reported 9,239 shares in the company. Cim Invest Mangement holds 10,153 shares or 0.03% of its portfolio. The Massachusetts-based Geode Capital Ltd Liability has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). The New York-based Incorporated has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Barclays Public Ltd holds 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 130 shares.

Insider Transactions: Since April 29, 2016, the stock had 0 insider buys, and 5 sales for $976,423 net activity. Another trade for 4,100 shares valued at $30,545 was sold by MCKEARN THOMAS J. The insider SIDRANSKY DAVID sold $342,348. On Friday, April 29 PETIT ROBERT sold $20,915 worth of the stock or 2,785 shares. O’Connor Daniel also sold $61,860 worth of Advaxis, Inc. (NASDAQ:ADXS) on Friday, April 29. The insider BERMAN RICHARD J sold 33,761 shares worth $520,755.

More notable recent Advaxis, Inc. (NASDAQ:ADXS) news were published by: which released: “Something Is Boiling Under The Surface At Advaxis” on October 05, 2016, also with their article: “Why Advaxis, Inc. Shares Are Soaring 11% Again Today” published on August 03, 2016, published: “Why Advaxis, Inc. Stock Rose 19.6% in May” on June 09, 2016. More interesting news about Advaxis, Inc. (NASDAQ:ADXS) were released by: and their article: “Here’s Why Advaxis Inc.’s Stock Roared Higher in March” published on April 12, 2016 as well as‘s news article titled: “Profit-Taking Clobbers Advaxis, Inc. in April Despite Positive PR” with publication date: May 08, 2016.

ADXS Company Profile

Advaxis, Inc., incorporated on February 28, 2002, is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. The Company’s Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants. The Company’s immunotherapy candidates include Axalimogene filolisbac (ADXS-HPV), ADXS-PSA and ADXS-HER2.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment